Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications.

Gastroesophageal reflux disease (GERD), a condition commonly encountered in the primary care setting, is a risk factor for adenocarcinoma of the esophagus. Despite the ubiquity of the complaint, considerable uncertainty exists with respect to several basic questions, including when to perform endoscopy in patients with chronic reflux symptoms and how to address the cancer risk associated with GERD. These clinical vignettes illustrate common clinical questions encountered in caring for patients with GERD, especially as they relate to the issue of cancer risk. Applying data reviewed in the companion article, we propose practical answers to common clinical situations regarding care of patients with reflux. We also present an algorithm for treatment of patients with chronic GERD symptoms.

[1]  R. Sampliner,et al.  Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. , 1999, Archives of internal medicine.

[2]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[3]  M Flüg,et al.  Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. , 1996, European journal of gastroenterology & hepatology.

[4]  R. Koehler,et al.  Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. , 1994, Gastroenterology.

[5]  P. Reinikainen,et al.  Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. , 1997, The American journal of gastroenterology.

[6]  C. Tinelli,et al.  Prevalence and Impact of Symptoms Suggestive of Gastroesophageal Reflux Disease , 1999, Digestive Diseases and Sciences.

[7]  R. Sandler,et al.  The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. , 1997, The American journal of gastroenterology.

[8]  D. Revicki,et al.  The Impact of Gastroesophageal Reflux Disease on Health-related Quality of Life 1 1 Supported by res , 1998 .

[9]  A. Klauser,et al.  Three year follow up of patients with gastrooesophageal reflux disease. , 1992, Gut.

[10]  R. Sampliner,et al.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. , 2001, JAMA.

[11]  Williams,et al.  A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects , 1998, Alimentary pharmacology & therapeutics.

[12]  F. Raiser,et al.  Laparoscopic Nissen fundoplication: where do we stand? , 1997, Surgical laparoscopy & endoscopy.

[13]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[14]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[15]  Levine,et al.  Complete resolution of heartburn symptoms and health‐related quality of life in patients with gastro‐oesophageal reflux disease , 1999, Alimentary pharmacology & therapeutics.

[16]  S. Kavic,et al.  Complications of endoscopy. , 2001, American journal of surgery.

[17]  C. Bate,et al.  A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. , 1994, Gastroenterology.

[18]  A. Sonnenberg,et al.  Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. , 2001, Gastroenterology.

[19]  D. Fleischer,et al.  Prospective analysis of complications 30 days after outpatient upper endoscopyFig. 1 , 1999, American Journal of Gastroenterology.

[20]  C. Pehl,et al.  The effect of decaffeination of coffee on gastro‐oesophageal reflux in patients with reflux disease , 1997, Alimentary pharmacology & therapeutics.

[21]  W. Chow,et al.  Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. , 2001, Gastroenterology.

[22]  D. Castell,et al.  Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. , 1988, The American journal of gastroenterology.

[23]  G. Falk,et al.  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999, American Journal of Gastroenterology.

[24]  I. Wiklund,et al.  Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. , 1999 .

[25]  J. Fraumeni,et al.  The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. , 1995, JAMA.

[26]  R. Sampliner.  Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. , 1994, The American journal of gastroenterology.

[27]  A. Hasman,et al.  Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. , 1995, Gastrointestinal endoscopy.

[28]  R. Sampliner,et al.  The omeprazole test is as sensitive as 24‐h oesophageal pH monitoring in diagnosing gastro‐oesophageal reflux disease in symptomatic patients with erosive oesophagitis , 2000, Alimentary pharmacology & therapeutics.

[29]  J. Stanford,et al.  Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer , 2000, Cancer Causes & Control.

[30]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[31]  J. Dent,et al.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. , 2000, Gastroenterology.

[32]  M F Chan,et al.  Complications of upper gastrointestinal endoscopy. , 1996, Gastrointestinal endoscopy clinics of North America.

[33]  G. Wetscher,et al.  Laparoscopic Nissen Fundoplication Is an Effective Treatment for Gastroesophageal Reflux Disease , 1994, Annals of surgery.

[34]  J. Coelho,et al.  Conversions and complications of laparoscopic treatment of gastroesophageal reflux disease. , 1999, Journal of the American College of Surgeons.

[35]  J. Dent,et al.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole. , 1988, Gastroenterology.

[36]  D. Fleischer,et al.  Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. , 1991, Gastrointestinal endoscopy.

[37]  USNR LCDR Otto T. Nebel MC,et al.  Symptomatic gastroesophageal reflux: Incidence and precipitating factors , 2005, The American Journal of Digestive Diseases.

[38]  M. Bloomston,et al.  Quality of life and antireflux medication use following laparoscopic Nissen fundoplication. , 1998, The American surgeon.

[39]  A R Zinsmeister,et al.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. , 1997, Gastroenterology.

[40]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.